- Home
- OBT vs BCYC Comparison
OBT vs BCYC Comparison
Compare OBT & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBT | BCYC |
|---|---|---|
| Founded | 1892 | 2009 |
| Country | United States | United Kingdom |
| Employees | 225 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.5M | 360.7M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OBT | BCYC |
|---|---|---|
| Price | $30.51 | $4.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $36.00 | $17.56 |
| AVG Volume (30 Days) | 48.8K | ★ 333.2K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | N/A | ★ 42.91 |
| EPS | ★ 2.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | $12.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.97 | $5.00 |
| 52 Week High | $37.99 | $10.13 |
Technical Indicators
Market Signals| Indicator | OBT | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 34.17 | 30.87 |
| Support Level | $29.33 | N/A |
| Resistance Level | $31.49 | $7.71 |
| Average True Range (ATR) | 1.12 | 0.27 |
| MACD | -0.45 | -0.03 |
| Stochastic Oscillator | 24.76 | 0.00 |
Price Performance
Historical ComparisonAbout OBT Orange County Bancorp Inc.
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.